Back to Discover

GOSS · Biotech · Nasdaq · As of 21 Nov 2026

Gossamer Bio, Inc. stock: filings, catalysts and timeline

Sign in to follow

AIR Score

0100
38

Weak · 38 / 100

AIR confidence

Support behind the full AIR read.

What is this? →

How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.

The Discovery Gap

LOWHIGHVERY HIGH

Medium

Gap confidence

How fully AIR could measure this Gap — separate from the AIR Score's confidence.

What is this? →

How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.

Five perspectives

  • FundamentalsWhat is this?Not scored — outside AIR's $300M–$20B fundamentals band

    How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.

    Source: SEC XBRL financial statements.

  • ValueWhat is this?Too few of the required measures on file

    How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.

    Source: SEC XBRL financial statements and end-of-day prices.

  • News flowWhat is this?Balanced

    What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.

    Source: SEC EDGAR 8-K filings and FDA approvals.

  • MomentumWhat is this?Weak

    The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.

    Source: End-of-day prices.

  • SafetyWhat is this?Watch

    The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.

    Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.

Rating words, not raw numbers.

How AIR scores →

Discovery Gap: Medium (16/100) · Gap confidence 57/100

Discovery gap

Some evidence isn't yet fully priced in.

Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.

What is this?

How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.

Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.

How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.

This month at a glance

AIR Score™ change: +4Moved up +4 on new evidence.
Window31 Oct 2026 → 21 Nov 2026
Momentum+3Lifted the score this month.
Safety+1Lifted the score this month.

Evidence timeline

  1. Expected
  2. Wed 17 Mar · expected 10-K

    Last year filed 17 Mar 2026.

  3. Mon 17 May · expected 10-Q

    Last year filed 15 May 2026.

  4. Filed
  5. Tue 10 Nov · 8-K

    8-K · Item 2.02 — Results of operations

    Gossamer submitted first NDA for seralutinib in PAH to FDA in September 2026. Secured $25M upfront with up to $125M additional capital upon FDA acceptance. Reacquired worldwide rights from Chiesi. Cash position $51.2M as of Q3 2026.

    Recognition: Weak 24 → Watch 38Gap Medium · 11 → Medium · 21

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

  6. Tue 10 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Weak 24 → Watch 38Gap Medium · 11 → Medium · 21

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

  7. Wed 28 Oct · 8-K

    Current report (8-K)

    Recognition: Watch 32 → Weak 24

    Market attention has faded.

    The price trend weakened.

  8. Mon 28 Sep · 8-K

    8-K · Item 8.01 — Other events

    News flow: first measured — Watch 43Recognition: first measured — Watch 37Gap first measured: Low · 0

    AIR measured this for the first time; no change to report.

  9. Wed 23 Sep · 8-K

    8-K · Item 8.01 — Other events

  10. Wed 16 Sep · 8-K

    8-K · Item 5.02 — Director or officer change

  11. Fri 11 Sep · 8-K

    8-K · Items 3.03, 8.01 — Change to shareholder rights

  12. Wed 9 Sep · 8-K

    8-K · Item 8.01 — Other events

  13. Thu 3 Sep · 8-K

    Current report (8-K)

  14. Wed 26 Aug · 8-K

    Current report (8-K)

  15. Fri 21 Aug · 8-K

    8-K · Items 1.01, 3.02 — Material agreement

  16. Thu 13 Aug · 10-Q

    Quarterly report (10-Q), period ending 30 Jun 2026

  17. Thu 13 Aug · 8-K

    8-K · Item 2.02 — Results of operations

  18. Mon 27 Jul · 8-K

    8-K · Items 1.01, 1.02, 2.02, 8.01 — Material agreement

  19. Wed 15 Jul · 8-K

    8-K · Item 5.02 — Director or officer change

  20. Wed 1 Jul · 8-K

    Current report (8-K)

  21. Wed 17 Jun · 8-K

    Current report (8-K)

  22. Fri 5 Jun · 8-K

    8-K · Items 1.01, 1.02, 2.03, 3.02 — Material agreement

  23. Fri 5 Jun · 8-K

    Current report (8-K)

  24. Tue 2 Jun · 8-K

    8-K · Item 8.01 — Other events

  25. Mon 18 May · 8-K

    8-K · Items 1.01, 2.02, 5.02, 8.01 — Material agreement

  26. Fri 15 May · 10-Q

    Quarterly report (10-Q), period ending 31 Mar 2026

  27. Thu 9 Apr · 8-K

    8-K · Item 3.01 — Listing notice

  28. Tue 17 Mar · 10-K

    Annual report (10-K), FY2025

  29. Tue 17 Mar · 8-K

    8-K · Item 2.02 — Results of operations

  30. Mon 23 Feb · 8-K

    8-K · Item 8.01 — Other events

Earlier →

Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, further risk-signal deterioration, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.